Navigation Links
Edwards' Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
Date:10/23/2007

fesciences

Edwards Lifesciences, a leader in advanced cardiovascular disease treatments, is the number-one heart valve company in the world and the global leader in acute hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards focuses on specific cardiovascular opportunities including heart valve disease, peripheral vascular disease and critical care technologies. The company's global brands, which are sold in nearly 100 countries, include Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, LifeStent, PERIMOUNT Magna, and Swan-Ganz. Additional company information can be found at http://www.edwards.com.

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to, those related to the expectation that the results from The RESILIENT Trial will establish the LifeStent self-expanding stent as a treatment alternative for certain patients. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experiences to differ materially from that expressed or implied by the forward-looking statements include those risks detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2006.

Edwards is a trademark of Edwards Lifesciences Corporation. Edwards Lifesciences, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz are trademar
'/>"/>

SOURCE Edwards Lifesciences Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
7. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...,Nov.24/PRNewswire-Asia/--HuifengBio-Pharmaceutica...eveloperandproducer,ofplantextractsandpharmaceutic...landfoodproductioninXi,an,China,todayreportedthati...revenues. , RevenuesforthequarterendedSept.30...om$3,534,623forthesamequarterin2008.Netincome,amou...
(Date:11/24/2009)...OOD,Calif.,Nov.24/PRNewswire-FirstCall/--IPCTheHos...alhospitalistphysiciangrouppracticecompany,announc...t,wasnamedby ACPHospitalist asoneofthe2009TopTenHo...2009issueofthemagazine. ,, Dr.Vaidyanhasbeenapr...vesasdirectorofhospitalmedicineatSt.Mary,sHealthCe...
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--ZimmerHoldings,Inc....atinginthe21stAnnualPiperJaffrayHealthCareConferen...ternTime. ,, Alivewebcastofthepresentationcanbe...://investor.zimmer.com .Thewebcastwillbearchivedfo...any ,, Foundedin1927andheadquarteredinWarsaw,I...
Breaking Medicine Technology:Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 2Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 3IPC The Hospitalist Company's Philip Vaidyan, M.D. Named a Top Hospitalist of 2009 2Watson Pharmaceuticals Resumes Shipment of INFeD 28R 29 28Iron Dextran Injection USP 29 51309 1Watson Pharmaceuticals Resumes Shipment of INFeD 28R 29 28Iron Dextran Injection USP 29 51309 2Watson Pharmaceuticals Resumes Shipment of INFeD 28R 29 28Iron Dextran Injection USP 29 51309 3Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 51307 1Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 51307 2Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 51307 3Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 1Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 2Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 3Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 4Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 5Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 6
...lood pressure reductions of 30.8 mm Hg,systolic bl...pressure (DBP),at five weeks and 21.1/19.3 mm Hg (... of patients with severe hypertension, AVAL...4.6 mm Hg (SBP/DBP), at 8 weeks, and 22.1/11.6 mm...ectively for irbesartan and HCTZ alone, in a study...
...Proprietary siRNA Molecule in Acute .... 19 Quark Pharmaceuticals, Inc., a,development-s... and,developing novel RNA interference-based thera...temic dosing in humans of its proprietary product,... developed by Quark for,the treatment of Acute Ren...
Other Medicine Technology:Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 2Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 3Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 4Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 5Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 6Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 7Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 2Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 3Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 4
(Date:11/24/2009)...Researchers at Ben-Gurion University of the Negev ... skin tumors, including melanomas that aren,t visi...the OSPI instrument (Optical Spectro-Polarimetric ...e never been seen before - including melanoma in p...ns and were awaiting surgery for their removal. Th...
(Date:11/24/2009)...Mid-Winter Meetings Jan. 27Feb. 2, 2010, at the Al...his year, SNM joins its annual Mid-Winter Educatio...cational Symposium of the American College of Nucl...r Imaging Summit and the Clinical Trials Network C...icipants an outstanding range of scientific conten...
(Date:11/24/2009)...sed sevenfold, study finds, , , TUESDAY...c-resistant infections normally found in the commu...tpatients, raising the risk that inpatients could ... to 2006, researchers found a sevenfold increase i...sistant Staphylococcus aureus (MRSA) infections....
(Date:11/24/2009)...ice to be coupled with Stem Cell Therapy. , ...24, 2009 -- Entest Biomedical, Inc. (OTCBB: ENTB... a manufacturer of lasers regarding the developmen...ed by Entest and used in conjunction with several ...ntest. These therapies are aimed at increasing eff...
(Date:11/24/2009)...o Get a Leg Up From the American Podiatric Medical...Md. (Vocus) November 24, 2009 -- The average perso... that number dramatically increases during the hol...continue making their holiday travel plans, it&rsq...runt of aches and pains while on the road. , , , ...
Breaking Medicine News(10 mins):Health News:New device enables early detection of cancerous skin tumors -- Ben Gurion U. 2Health News:SNM's Conjoint Mid-Winter Meetings offer 4 scientific meetings in 1 location 2Health News:MRSA Creeping Into Hospitals From the Outside 2Health News:MRSA Creeping Into Hospitals From the Outside 3Health News:Entest Biomedical Enters into Discussions with Laser Manufacturer to Develop Proprietary Photoceutical Device for COPD Treatment 2Health News:Keep Holiday Travel Foot-Friendly 2Health News:Keep Holiday Travel Foot-Friendly 3
...egarding the outbreak of the deadly Rift valley Fe...warned against consumption of raw milk. // ...en borderline areas, is safe from the viral livest...due to hygienic concerns but also due to the fact ...
...linois at Chicago study published in the January i...ority of fertility clinic Web sites does not adher...nes. The study also found that services offer... offer financial incentives. Many consumers re...
...ts that doctors should advise and persuade patient...heir partners and bring// them for check up and tr...g kits or drugs in order to help reduce infection ...ransmitted infections often makes this difficult. ...
...ency, Pharmac, is in the process of doing away wit... Pharmac intends to phase out the ‘Aropax’ brand ... ‘Loxamine’. It is estimated that Aropax is used b...e, except for the appearance and the packaging. Fu...
...ake Forest University Baptist Medical Center are h...lving 83 other sites that will test 3,000 patients... is good for heart failure patients. Though d...he group of patients who primarily have heart fail...
... we shed tears. But exactly what our tears are mad... A new study sheds some light on the complex desig...call tear film, which is made up of three distinct...layer of fatty, oily substances collectively calle...
Other Medicine News:Health News:Experts Warn Against Raw Milk Following Rift Valley Fever Outbreak in Kenya 2Health News:Experts Warn Against Raw Milk Following Rift Valley Fever Outbreak in Kenya 3Health News:Fertility Clinic Web Sites Doesn’t Adhere to Ad-Guideline 2Health News:New International Study to Test Exercise in Heart Failure Patients 2Health News:New International Study to Test Exercise in Heart Failure Patients 3Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 2Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 3
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
Medicine Products: